Related Experiment Video
Updated: Jun 28, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Novel bifunctional natriuretic peptides as potential therapeutics
Deborah M Dickey1, John C Burnett, Lincoln R Potter
1Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, USA.
The Journal of Biological Chemistry
|October 23, 2008
Summary
A novel chimeric peptide, CD-NP, enhances kidney function by modifying natriuretic peptide receptor activity. This peptide shows promise as a new therapeutic for heart failure, improving upon existing treatments.
Area of Science:
- Cardiovascular Pharmacology
- Renal Physiology
- Peptide Therapeutics
Background:
- Synthetic atrial natriuretic peptide (carperitide) and B-type natriuretic peptide (BNP; nesiritide) treat heart failure but are limited by reduced renal perfusion.
- A chimeric peptide, CD-NP (C-type natriuretic peptide fused to Dendroaspis natriuretic peptide tail), enhances glomerular filtration rate more than BNP in dogs.
- The molecular mechanisms behind CD-NP's enhanced responsiveness were previously undetermined.
Purpose of the Study:
- To elucidate the molecular basis for CD-NP's enhanced glomerular filtration rate (GFR) activity.
- To investigate the effects of the Dendroaspis natriuretic peptide (DNP) tail on natriuretic peptide receptor (NPR) activation.
- To engineer chimeric peptides with improved potency and efficacy for natriuretic peptide receptor A (NPR-A).
Main Methods:
- Investigated the interaction of CD-NP and its components with human and rat natriuretic peptide receptors (NPR-A, NPR-B, NPR-C).
- Assessed the agonist activity and receptor binding affinities of CD-NP, DNP tail, and engineered variants.
- Modified specific amino acid sequences within the C-type natriuretic peptide (CNP) ring of CD-NP to mimic B-type natriuretic peptide (BNP) sequences.
Main Results:
- The DNP tail converted CNP from a non-agonist to a partial agonist of human NPR-A, while retaining NPR-B activation.
- CD-NP showed species-specific effects on NPR-A, being a stronger activator in humans than rats.
- Engineered CD-NP variants with BNP-like sequences exhibited significantly increased affinity and full agonist activity for NPR-A, with one variant matching known potent activators.
- DNP was found to bind the natriuretic peptide clearance receptor (NPR-C), but chimeric peptides did not show significantly higher affinity than endogenous ligands.
Conclusions:
- The DNP tail significantly modulates CNP's activity at natriuretic peptide receptors, enhancing NPR-A agonism.
- Bifunctional chimeric peptides, like CD-NP, represent a promising new class of therapeutics for cardiovascular and renal conditions.
- Further development of these engineered peptides could lead to more effective treatments for heart failure by optimizing renal perfusion and cardiac unloading.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...